Ad is loading...
MNKD
Price
$6.80
Change
-$0.22 (-3.13%)
Updated
Nov 15 closing price
107 days until earnings call
NTLA
Price
$13.97
Change
-$1.15 (-7.61%)
Updated
Nov 15 closing price
95 days until earnings call
Ad is loading...

MNKD vs NTLA

Header iconMNKD vs NTLA Comparison
Open Charts MNKD vs NTLABanner chart's image
MannKind
Price$6.80
Change-$0.22 (-3.13%)
Volume$5.22M
CapitalizationN/A
Intellia Therapeutics
Price$13.97
Change-$1.15 (-7.61%)
Volume$3.69M
CapitalizationN/A
MNKD vs NTLA Comparison Chart
Loading...
MNKD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
MNKD vs. NTLA commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNKD is a Sell and NTLA is a StrongSell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (MNKD: $6.80 vs. NTLA: $13.97)
Brand notoriety: MNKD and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNKD: 226% vs. NTLA: 159%
Market capitalization -- MNKD: $1.88B vs. NTLA: $1.42B
MNKD [@Biotechnology] is valued at $1.88B. NTLA’s [@Biotechnology] market capitalization is $1.42B. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNKD’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • MNKD’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, MNKD is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNKD’s TA Score shows that 2 TA indicator(s) are bullish while NTLA’s TA Score has 5 bullish TA indicator(s).

  • MNKD’s TA Score: 2 bullish, 6 bearish.
  • NTLA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than MNKD.

Price Growth

MNKD (@Biotechnology) experienced а -7.42% price change this week, while NTLA (@Biotechnology) price change was -16.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

MNKD is expected to report earnings on Mar 04, 2025.

NTLA is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNKD($1.88B) has a higher market cap than NTLA($1.42B). MNKD YTD gains are higher at: 86.813 vs. NTLA (-54.182). MNKD has higher annual earnings (EBITDA): 53.3M vs. NTLA (-514.18M). NTLA has more cash in the bank: 691M vs. MNKD (248M). NTLA has less debt than MNKD: NTLA (106M) vs MNKD (231M). MNKD has higher revenues than NTLA: MNKD (248M) vs NTLA (46M).
MNKDNTLAMNKD / NTLA
Capitalization1.88B1.42B132%
EBITDA53.3M-514.18M-10%
Gain YTD86.813-54.182-160%
P/E Ratio85.00N/A-
Revenue248M46M539%
Total Cash248M691M36%
Total Debt231M106M218%
FUNDAMENTALS RATINGS
MNKD vs NTLA: Fundamental Ratings
MNKD
NTLA
OUTLOOK RATING
1..100
828
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
33
Fair valued
PROFIT vs RISK RATING
1..100
1996
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
3893
P/E GROWTH RATING
1..100
84100
SEASONALITY SCORE
1..100
2850

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (33) in the Biotechnology industry is somewhat better than the same rating for MNKD (76). This means that NTLA’s stock grew somewhat faster than MNKD’s over the last 12 months.

MNKD's Profit vs Risk Rating (19) in the Biotechnology industry is significantly better than the same rating for NTLA (96). This means that MNKD’s stock grew significantly faster than NTLA’s over the last 12 months.

NTLA's SMR Rating (95) in the Biotechnology industry is in the same range as MNKD (100). This means that NTLA’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for NTLA (93). This means that MNKD’s stock grew somewhat faster than NTLA’s over the last 12 months.

MNKD's P/E Growth Rating (84) in the Biotechnology industry is in the same range as NTLA (100). This means that MNKD’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNKDNTLA
RSI
ODDS (%)
Bearish Trend 3 days ago
73%
Bullish Trend 3 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
68%
Bullish Trend 3 days ago
87%
Momentum
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
82%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 12 days ago
87%
Bullish Trend 7 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
78%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
74%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
MNKD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TOLIX16.770.15
+0.90%
DWS RREEF Global Infrastructure Inst
PREAX6.95N/A
N/A
PACE Global Real Estate Securities A
RDERX18.01-0.07
-0.39%
Columbia Large Cap Value Adv
MCBVX32.79-0.22
-0.67%
MFS Mid Cap Value B
DBOCX24.71-0.22
-0.88%
BNY Mellon Balanced Opportunity C

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with QSI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then QSI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
-3.13%
QSI - MNKD
44%
Loosely correlated
-5.77%
NTLA - MNKD
44%
Loosely correlated
-7.61%
VCYT - MNKD
44%
Loosely correlated
-2.97%
BEAM - MNKD
43%
Loosely correlated
-8.59%
PGEN - MNKD
42%
Loosely correlated
-7.11%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-7.61%
VCYT - NTLA
69%
Closely correlated
-2.97%
EDIT - NTLA
68%
Closely correlated
-3.97%
BEAM - NTLA
67%
Closely correlated
-8.59%
CRSP - NTLA
64%
Loosely correlated
+0.85%
PRME - NTLA
58%
Loosely correlated
-6.95%
More